River Global Investors LLP Acquires 45,392 Shares of MaxCyte, Inc. (NASDAQ:MXCT)

River Global Investors LLP boosted its holdings in shares of MaxCyte, Inc. (NASDAQ:MXCT) by 3.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,518,646 shares of the company’s stock after buying an additional 45,392 shares during the period. MaxCyte makes up about 1.3% of River Global Investors LLP’s holdings, making the stock its 15th largest holding. River Global Investors LLP owned 1.46% of MaxCyte worth $7,053,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in MXCT. Willis Investment Counsel bought a new stake in MaxCyte during the fourth quarter valued at $2,585,000. Maven Securities LTD bought a new stake in MaxCyte during the third quarter worth about $637,000. Blair William & Co. IL lifted its stake in MaxCyte by 94.4% during the third quarter. Blair William & Co. IL now owns 251,851 shares of the company’s stock worth $786,000 after purchasing an additional 122,326 shares during the last quarter. Valmark Advisers Inc. bought a new stake in MaxCyte during the fourth quarter worth about $394,000. Finally, SG Americas Securities LLC bought a new stake in MaxCyte during the third quarter worth about $118,000. Institutional investors own 68.81% of the company’s stock.

MaxCyte Price Performance

NASDAQ:MXCT traded down $0.06 during mid-day trading on Friday, reaching $3.77. 477,877 shares of the company’s stock traded hands, compared to its average volume of 451,874. MaxCyte, Inc. has a 12-month low of $2.45 and a 12-month high of $5.55. The firm has a market capitalization of $394.12 million, a price-to-earnings ratio of -10.19 and a beta of 1.36. The company has a 50 day moving average price of $4.13 and a 200-day moving average price of $4.34.

MaxCyte (NASDAQ:MXCT) last posted its earnings results on Tuesday, March 12th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.05. MaxCyte had a negative return on equity of 15.90% and a negative net margin of 91.85%. The firm had revenue of $15.67 million for the quarter, compared to the consensus estimate of $15.60 million. As a group, analysts forecast that MaxCyte, Inc. will post -0.53 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. BTIG Research decreased their price objective on MaxCyte from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, March 13th. Stephens restated an “overweight” rating and set a $11.00 price target on shares of MaxCyte in a report on Tuesday, April 23rd. Finally, William Blair restated an “outperform” rating on shares of MaxCyte in a report on Wednesday, March 13th.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.